Pharsight

Woodward patents expiration

1. Aciphex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5045552 WOODWARD Pyridine derivatives having anti-ulcerative activity
May, 2013

(11 years ago)

US5045552

(Pediatric)

WOODWARD Pyridine derivatives having anti-ulcerative activity
Nov, 2013

(10 years ago)

Drugs and Companies using RABEPRAZOLE SODIUM ingredient

Market Authorisation Date: 29 May, 2002

Treatment: Treatment of peptic ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ACIPHEX before it's drug patent expiration?
More Information on Dosage

ACIPHEX family patents

Family Patents

2. Avandia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5741803 WOODWARD Substituted thiazolidinedionle derivatives
Apr, 2015

(9 years ago)

US5741803

(Pediatric)

WOODWARD Substituted thiazolidinedionle derivatives
Oct, 2015

(8 years ago)

US6288095 WOODWARD Compounds
Feb, 2017

(7 years ago)

US6288095

(Pediatric)

WOODWARD Compounds
Aug, 2017

(6 years ago)

US7358366 WOODWARD Thiazolidinedione derivative and its use as antidiabetic
Apr, 2020

(4 years ago)

US7358366

(Pediatric)

WOODWARD Thiazolidinedione derivative and its use as antidiabetic
Oct, 2020

(3 years ago)

Drugs and Companies using ROSIGLITAZONE MALEATE ingredient

Market Authorisation Date: 25 May, 1999

Treatment: Use of avandia as monotherapy, in combination with metformin, and in combination with sulfonylureas to improve glycemic control in patients with type 2 diabetes mellitus; Method of treatment of type i...

Dosage: TABLET;ORAL

How can I launch a generic of AVANDIA before it's drug patent expiration?
More Information on Dosage

AVANDIA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Coreg patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40000 WOODWARD Method of treatment for decreasing mortality resulting from congestive heart failure
Jun, 2015

(9 years ago)

USRE40000

(Pediatric)

WOODWARD Method of treatment for decreasing mortality resulting from congestive heart failure
Dec, 2015

(8 years ago)

Drugs and Companies using CARVEDILOL ingredient

Market Authorisation Date: 29 May, 1997

Treatment: Decreasing mortality caused by congestive heart failure

Dosage: TABLET;ORAL

How can I launch a generic of COREG before it's drug patent expiration?
More Information on Dosage

COREG family patents

Family Patents

4. Coreg Cr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE40000 WOODWARD Method of treatment for decreasing mortality resulting from congestive heart failure
Jun, 2015

(9 years ago)

US6022562 WOODWARD Medicinal and/or nutritional microcapsules for oral administration
Oct, 2015

(8 years ago)

USRE40000

(Pediatric)

WOODWARD Method of treatment for decreasing mortality resulting from congestive heart failure
Dec, 2015

(8 years ago)

US6022562

(Pediatric)

WOODWARD Medicinal and/or nutritional microcapsules for oral administration
Apr, 2016

(8 years ago)

US7268156 WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Jun, 2023

(11 months ago)

US7268156

(Pediatric)

WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Dec, 2023

(5 months ago)

US8101209 WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(1 year, 2 months from now)

US8101209

(Pediatric)

WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Mar, 2026

(1 year, 8 months from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Decreasing mortality caused by congestive heart failure; Treatment of hypertension

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents

5. Jalyn patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5998427 WOODWARD Androstenones
Sep, 2013

(10 years ago)

US5846976 WOODWARD Androstenone derivative
Sep, 2013

(10 years ago)

US5565467 WOODWARD Androstenone derivative
Nov, 2015

(8 years ago)

Drugs and Companies using DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 June, 2010

Treatment: Method of treating an androgen response or mediated disease in a mammal by administering an effective androgen responsive or medicated disease amount of dutasteride..conditions include benign prostati...

Dosage: CAPSULE;ORAL

How can I launch a generic of JALYN before it's drug patent expiration?
More Information on Dosage

JALYN family patents

Family Patents

6. Lovaza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5502077 WOODWARD Fatty acid composition
Mar, 2013

(11 years ago)

US5656667 WOODWARD Fatty acid composition
Apr, 2017

(7 years ago)

US7732488 WOODWARD Pharmaceutical composition comprising low concentrations of environmental pollutants
Jan, 2025

(7 months from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-87) Sep 16, 2012

Drugs and Companies using OMEGA-3-ACID ETHYL ESTERS ingredient

Market Authorisation Date: 10 November, 2004

Treatment: Use in lipid management

Dosage: CAPSULE;ORAL

How can I launch a generic of LOVAZA before it's drug patent expiration?
More Information on Dosage

LOVAZA family patents

Family Patents

7. Lunesta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381724

(Pediatric)

WOODWARD Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same
Jul, 2012

(11 years ago)

US6319926

(Pediatric)

WOODWARD Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it
Jul, 2012

(11 years ago)

US6864257 WOODWARD Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
Aug, 2012

(11 years ago)

US6864257

(Pediatric)

WOODWARD Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
Mar, 2013

(11 years ago)

US6444673 WOODWARD Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
Feb, 2014

(10 years ago)

US6444673

(Pediatric)

WOODWARD Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it
Aug, 2014

(9 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Apr 10, 2016
M(M-61) Oct 10, 2015

Drugs and Companies using ESZOPICLONE ingredient

Market Authorisation Date: 15 December, 2004

Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone

Dosage: TABLET;ORAL

How can I launch a generic of LUNESTA before it's drug patent expiration?
More Information on Dosage

LUNESTA family patents

Family Patents